Real-World Experience with Oritavancin Therapy in Invasive Gram-Positive Infections
INTRODUCTION: Oritavancin is a novel lipoglycopeptide approved for acute bacterial skin and skin structure infections. The pharmacokinetic profile and convenient one-time dosing make oritavancin an enticing option for other serious Gram-positive infections requiring prolonged treatment courses. Unfortunately, data for using oritavancin in these populations are limited.
METHODS: We report ten cases of oritavancin use for invasive Gram-positive infections in our health system, and provide a review of the currently available literature regarding oritavancin therapy for invasive infections.
RESULTS: Among the ten patients who received oritavancin, the most common infection was methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia (n = 5, 50%). Other indications for oritavancin use included methicillin-resistant S. aureus (MRSA) bursitis (n = 1, 10%), group B streptococcal bacteremia with native tricuspid valve infective endocarditis (n = 1, 10%), coagulase-negative staphylococcal bacteremia (n = 1, 10%), MSSA deep tissue infection (n = 1, 10%), and enterococcal bacteremia (n = 1, 10%). Oritavancin was well tolerated, and 7/10 (70%) patients were successfully treated.
CONCLUSION: Oritavancin is a potential option for patients with invasive Gram-positive infections. Further study is warranted.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
Infectious diseases and therapy - 6(2017), 2 vom: 10. Juni, Seite 277-289 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Stewart, Cassie L [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bacteremia |
|---|
| Anmerkungen: |
Date Revised 09.04.2022 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1007/s40121-017-0156-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM270744843 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM270744843 | ||
| 003 | DE-627 | ||
| 005 | 20231224231221.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40121-017-0156-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0902.xml |
| 035 | |a (DE-627)NLM270744843 | ||
| 035 | |a (NLM)28386776 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Stewart, Cassie L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Real-World Experience with Oritavancin Therapy in Invasive Gram-Positive Infections |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 09.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a INTRODUCTION: Oritavancin is a novel lipoglycopeptide approved for acute bacterial skin and skin structure infections. The pharmacokinetic profile and convenient one-time dosing make oritavancin an enticing option for other serious Gram-positive infections requiring prolonged treatment courses. Unfortunately, data for using oritavancin in these populations are limited | ||
| 520 | |a METHODS: We report ten cases of oritavancin use for invasive Gram-positive infections in our health system, and provide a review of the currently available literature regarding oritavancin therapy for invasive infections | ||
| 520 | |a RESULTS: Among the ten patients who received oritavancin, the most common infection was methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia (n = 5, 50%). Other indications for oritavancin use included methicillin-resistant S. aureus (MRSA) bursitis (n = 1, 10%), group B streptococcal bacteremia with native tricuspid valve infective endocarditis (n = 1, 10%), coagulase-negative staphylococcal bacteremia (n = 1, 10%), MSSA deep tissue infection (n = 1, 10%), and enterococcal bacteremia (n = 1, 10%). Oritavancin was well tolerated, and 7/10 (70%) patients were successfully treated | ||
| 520 | |a CONCLUSION: Oritavancin is a potential option for patients with invasive Gram-positive infections. Further study is warranted | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Bacteremia | |
| 650 | 4 | |a Extended duration | |
| 650 | 4 | |a Lipoglycopeptide | |
| 650 | 4 | |a OPAT | |
| 650 | 4 | |a Outpatient parenteral antimicrobial therapy | |
| 650 | 4 | |a Staphylococci | |
| 650 | 4 | |a Staphylococcus aureus | |
| 700 | 1 | |a Turner, Michelle S |e verfasserin |4 aut | |
| 700 | 1 | |a Frens, Jeremy J |e verfasserin |4 aut | |
| 700 | 1 | |a Snider, Cynthia B |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Jordan R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Infectious diseases and therapy |d 2012 |g 6(2017), 2 vom: 10. Juni, Seite 277-289 |w (DE-627)NLM240483693 |x 2193-8229 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2017 |g number:2 |g day:10 |g month:06 |g pages:277-289 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s40121-017-0156-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2017 |e 2 |b 10 |c 06 |h 277-289 | ||